Poly Medicure Limited has submitted its investor presentation for the third quarter and nine months ended December 31, 2025, to BSE Limited and National Stock Exchange of India Limited under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation accompanies the company's unaudited financial results and provides comprehensive insights into operational performance and strategic developments.

Regulatory Compliance and Submission

The company filed the investor presentation on February 5, 2026, in compliance with Regulation 30, Regulation 51, and other applicable provisions of SEBI regulations. Company Secretary Avinash Chandra digitally signed the submission documents, ensuring proper regulatory adherence.

Financial Performance Highlights

The investor presentation reveals strong consolidated revenue growth with the company achieving ₹493.66 crores in Q3FY26 revenue, representing 16.4% year-over-year growth. The nine-month consolidated revenue reached ₹1,340.75 crores, demonstrating sustained business momentum.

Strategic Business Updates

The presentation highlights significant regulatory approvals and clinical progress, including DCGI approval for Intravenous Lithotripsy System (IVL) and Drug Eluting Balloon (DEB). The company's RisoR stent clinical study continues with over 200 patients enrolled across centers in India.

Market Position and Recognition

Poly Medicure received notable industry recognition, being awarded "Top 50 IP-Driven Organizations" by Confederation of Indian Industry and "Emerging Medical Devices Company of the Year in Cardiology" at VOH BEAT 2025. The company maintains adequate liquidity of ₹839.8 crores and completed capex spend of ₹234 crores in nine months.

Trade Deal Impact Analysis

The presentation addresses potential benefits from India-US and India-EU trade deals, highlighting reduced US tariffs from 50% to approximately 18% for medical devices. This development positions the company favorably for export expansion and enhanced competitiveness against Chinese imports in global markets.

The investor presentation is available on the company's website and provides stakeholders with detailed financial analysis, operational updates, and strategic outlook for continued growth in the medical devices sector.

Poly Medicure Ltd. recorded a substantial block trade on the National Stock Exchange (NSE), marking significant institutional activity in the healthcare sector. The transaction represents one of the notable block deals executed in the mid-cap healthcare space.

Block Trade Details

The NSE block trade involved substantial volume and value, demonstrating significant institutional participation in the company's stock.

Market Significance

Block trades typically involve large institutional investors and represent significant market transactions. The execution of approximately 953,661 shares at ₹1,648.20 per share indicates substantial institutional interest in Poly Medicure's stock. Such transactions are often conducted by institutional investors, mutual funds, or other large market participants seeking to execute substantial volumes without impacting regular market trading.

Company Profile

Poly Medicure operates in the healthcare sector and is classified as a mid-cap stock. The company's stock trades on both major Indian exchanges, with the recent block trade highlighting continued institutional engagement with the healthcare sector.

The block trade execution at ₹1,648.20 per share provides insight into the institutional valuation of the company's stock and reflects the ongoing market dynamics in the healthcare sector.